Clinical Trials Directory

Trials / Completed

CompletedNCT03569579

CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)

A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of D797 on Pharmacokinetics of D324 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Chong Kun Dang Pharmaceutical · Industry
Sex
All
Age
19 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction between D797 of D324 in healthy volunteers

Detailed description

To healthy subjects of twenty(20), following treatments are administered dosing in each period and wash-out period is a minimum of 21 days.

Conditions

Interventions

TypeNameDescription
DRUGMemantine Tab. 10mgMemantine Tab. 10mg\* 2T/day, QD, PO
DRUGMemantine Tab. 10mg + Donepezil Tab. 10mgMemantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO

Timeline

Start date
2018-04-16
Primary completion
2018-05-21
Completion
2018-06-04
First posted
2018-06-26
Last updated
2018-06-26

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03569579. Inclusion in this directory is not an endorsement.

CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1) (NCT03569579) · Clinical Trials Directory